Experienced in Memory Loss

Dr. David A. Rosenberg

Neurology
10941 Bloomfield St, Suite A, 
Los Alamitos, CA 
Experienced in Memory Loss
10941 Bloomfield St, Suite A, 
Los Alamitos, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Rosenberg is a Neurologist in Los Alamitos, California. Dr. Rosenberg is rated as an Experienced provider by MediFind in the treatment of Memory Loss. His top areas of expertise are Migraine with Brainstem Aura, Familial Hemiplegic Migraine, Memory Loss, and Olivopontocerebellar Atrophy.

His clinical research consists of participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 2 clinical trials in the study of Memory Loss.

Specialties
Neurology
Licenses
Psychiatry & Neurology in CA
Hospital Affiliations
Uci Health - Los Alamitos
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

10941 Bloomfield St, Suite A, Los Alamitos, CA 90720

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Rostock International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study
Rostock International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study
Enrollment Status: Active_not_recruiting
Publish Date: September 20, 2024
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With Attention-Deficit/Hyperactivity Disorder
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With Attention-Deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: February 13, 2024
Intervention Type: Drug
Study Drug: SPN-812
Study Phase: Phase 3
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological, Other
Study Drug: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Phase: Phase 3
Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers
Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers
Enrollment Status: Completed
Publish Date: November 15, 2022
Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: LY3303560
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Flexible-Dose Study of the Efficacy and Safety of SPN-812 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Flexible-Dose Study of the Efficacy and Safety of SPN-812 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: July 12, 2022
Intervention Type: Drug
Study Phase: Phase 3
A, Multi-center, Double-blind, Randomized, Placebo-controlled Study for the Efficacy of Phosphatidylserine in Mild Cognitive Impairment (MCI)
A, Multi-center, Double-blind, Randomized, Placebo-controlled Study for the Efficacy of Phosphatidylserine in Mild Cognitive Impairment (MCI)
Enrollment Status: Terminated
Publish Date: February 05, 2018
Intervention Type: Other
Study Phase: Not Applicable
View 10 Less Clinical Trials
Similar Doctors
Distinguished in Memory Loss
Dr. William R. Shankle
Neurology
Distinguished in Memory Loss
Dr. William R. Shankle
Neurology

William R Shankle MD Inc

3900 W Coast Hwy, Suite 310, 
Newport Beach, CA 
 (14.7 miles away)
949-478-8858
Languages Spoken:
English
See accepted insurances
Offers Telehealth

William Shankle is a Neurologist in Newport Beach, California. Dr. Shankle is rated as a Distinguished provider by MediFind in the treatment of Memory Loss. His top areas of expertise are Alzheimer's Disease, Memory Loss, Cerebellar Degeneration, and Dementia.

Distinguished in Memory Loss
Dr. Colin W. Stokol
Neurology
Distinguished in Memory Loss
Dr. Colin W. Stokol
Neurology
8631 W 3rd St, Suite 1025e, 
Los Angeles, CA 
 (26.0 miles away)
310-855-5999
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Colin Stokol is a Neurologist in Los Angeles, California. Dr. Stokol is rated as a Distinguished provider by MediFind in the treatment of Memory Loss. His top areas of expertise are Memory Loss, Axillary Nerve Dysfunction, New Daily Persistent Headache (NDPH), Stroke, and Thrombectomy.

Distinguished in Memory Loss
Dr. Daniel W. Chang
Neurology
Distinguished in Memory Loss
Dr. Daniel W. Chang
Neurology
500 S Virgil Ave, Suite 503, 
Los Angeles, CA 
 (22.1 miles away)
Languages Spoken:
English
See accepted insurances

Daniel Chang is a Neurologist in Los Angeles, California. Dr. Chang is rated as a Distinguished provider by MediFind in the treatment of Memory Loss. His top areas of expertise are Memory Loss, Epilepsy, Movement Disorders, and Parkinson's Disease.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rosenberg's expertise for a condition
ConditionClose
      View All 15 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile